Monday, August 24, 2015 9:31:18 AM
"(2) Based in part on information provided in a Form 4 filed on December 22, 2014. The shares beneficially owned by Lambda Investors may be deemed beneficially owned by Wexford Capital LP, which is the managing member of Lambda Investors, Wexford GP LLC, which is the General Partner of Wexford Capital LP, by Charles E. Davidson in his capacity as Chairman and managing member of Wexford Capital LP and by Joseph M. Jacobs in his capacity as President and managing member of Wexford Capital LP. The address of each of Lambda Investors LLC, Wexford Capital LP, Mr. Davidson and Mr. Jacobs is c/o Wexford Capital LP, 411 West Putnam Avenue, Greenwich, CT 06830. Each of Wexford Capital LP, Wexford GP LLC, Mr. Davidson and Mr. Jacobs disclaims beneficial ownership of the shares of Common Stock owned by Lambda Investors except, in the case of Mr. Davidson and Mr. Jacobs, to the extent of their respective interests in each member of Lambda Investors. Includes 11,742,100 shares issuable upon exercise of warrants held by Lambda Investors having an exercise price of $0.30 per share and 2,782,576 shares issuable upon exercise of warrants held by Lambda Investors having an exercise price of $0.40 per share. Lambda Investors is controlled by Wexford Capital LP. Arthur H. Amron, one of our directors, is a Partner and General Counsel of Wexford Capital LP. Paul A. Mieyal, one of our directors and former Acting President, Acting Chief Executive Officer, and Acting Chief Financial Officer until April 15, 2015, is a Vice President of Wexford Capital LP."
"The following table sets forth the beneficial ownership of our common stock as of June 30, 2015, by (i) each person known to us to own beneficially more than five percent (5%) of our common stock, based on such persons’ or entities’ filings with the SEC as of that date; (ii) each director and named executive officer; and (iii) all directors and executive officers as a group:
Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage of Class (1)
Lambda Investors LLC(2) 29,990,870 64.1 %"
Is this a share selling scam???
As with all pennystocks, time will tell...
They certainly have struggled...and had many problems with the FDA...
Including the FDA jerking them around for 15 MONTHS...
failing to even give them an ANSWER!
And the shareholders have suffered, while the officers pay themselves nice salaries...
again typical... LMAO
But I said a long time ago...I'll bail when Wexford/Lambda does...
and I'm sticking with that.
Lincoln Park is NOT the friend of any shareholder though...
just my opinion...of course....
Recent NEPH News
- Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 09:15:00 PM
- Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 02/29/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:17:43 PM
- Nephros Announces Results for Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/08/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:05:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:30:14 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:29:28 PM
- Nephros Hires Judy Krandel as Chief Financial Officer • GlobeNewswire Inc. • 11/01/2023 11:30:00 AM
- Nephros Schedules Third Quarter 2023 Financial Results Conference Call • GlobeNewswire Inc. • 10/25/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 08:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:15:27 PM
- Nephros Announces Results for Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/09/2023 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:00:51 PM
- Nephros Schedules Second Quarter 2023 Financial Results Conference Call • GlobeNewswire Inc. • 07/26/2023 11:30:00 AM
- Nephros Announces Results for Quarter Ended March 31, 2023 • GlobeNewswire Inc. • 05/10/2023 08:15:00 PM
- Nephros Announces CEO Retirement and Succession Plan • GlobeNewswire Inc. • 05/08/2023 11:30:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM